The Persistent Problem of Overuse of Diagnostic Testing Among House Staff-Time to Move Forward
I was a second-year medical student at the University of Pennsylvania, Philadelphia, in 1978 , and I had the immense good fortune to work with Sankey Williams, MD, and John Eisenberg, MD. They were performing a trial to evaluate the influence of education on reducing house staff use of unnecessary inpatient laboratory testing. 1 The educational intervention had no benefit on house staff ordering behavior, but it had resounding effects on how I came to view routine use of many different types of testing and treatments that I had previously assumed were evidence based. That early research experience led me to carefully question the evidence base for many commonly used tests and pro 
Prohibited Stimulants in Dietary Supplements After Enforcement Action by the US Food and Drug Administration
The US Food and Drug Administration (FDA) is responsible for eliminating adulterated and potentially hazardous dietary supplements from the marketplace. The FDA uses a variety of enforcement actions, including public notices, to remove potentially hazardous ingredients. However, it is not known whether public notices are effective. We explored the effectiveness of the FDA's public notices issued between 2013 and 2016 targeting prohibited sympathomimetic stimulants in supplements. We analyzed supplements purchased in 2014 and the same brands purchased again in 2017 to determine the presence of prohibited stimulants before and after the FDA issued public notices.
Methods | From January 1, 2013, to December 31, 2016, the FDA issued notices regarding 4 prohibited sympathomimetic stimulants: 1,3-dimethylamylamine (1,3-DMAA), 1,3-dimethylbutylamine (DMBA), β-methylphenylethylamine (BMPEA), and methylsynephrine (oxilofrine). [1] [2] [3] [4] The FDA notices regarding ingredients in supplements not categorized as sympathomimetic stimulants, such as picamilon, were excluded from the current analysis. We previously analyzed all supplements on sale in 2014 listing Acacia rigidula as an ingredient for the presence of 1 stimulant, BMPEA. 1 For the current study, we purchased the same brands of supplements in 2017. Supplements purchased in 2014 were reanalyzed for 1,3-DMAA, DMBA, and oxilofrine, and supplements purchased in 2017 were analyzed for all 4 prohibited stimulants subject to FDA enforcement action. As previously described, 1 liquid chromatography-quadrupole time-offlight mass spectrometry was used to analyze the supplements, and the presence of each stimulant was confirmed by accurate mass, retention time, isotope pattern, and at least 1 fragment ion in the mass spectra.
Results | Of the 21 brands of supplements analyzed in 2014, a total of 12 brands (57%) were still available for purchase in 2017. The 12 brands that were available in both 2014 and 2017 were included in the current analysis (Table) . In 2013, the FDA issued a public notice about the use of 1,3-DMAA. Of the 12 supplements purchased in 2014, 1,3-DMAA was present in 6 (50%). The FDA issued notices about the use of DMBA and BMPEA in 2015 and oxilofrine in 2016. Of the 12 supplements purchased in 2017, a total of 9 (75%) contained at least 1 of the 4 stimulants subject to FDA notices, and 6 (50%) contained 2 or more. One stimulant, DMBA, was not detected in any supplement purchased in 2014. After the FDA issued a public notice about DMBA in 2015, DMBA was detected in 4 of the 12 supplements (33%) purchased in 2017.
Editor's Note page 1723 Discussion | To eliminate potentially hazardous supplements from the marketplace, the FDA recalls individual products and issues public notices regarding individual ingredients. The effectiveness of FDA recalls of individual products has been previously studied. 5, 6 One analysis 6 found that 67% of brands subject to FDA recalls still on sale contained adulterants. Our current study explores the use of public notices targeting individual ingredients in supplements rather than individual products. Two findings are notable. First, the number of products that contained 1,3-DMAA, BMPEA, and oxilofrine decreased, but most supplements tested contained 1 or more prohibited stimulant, some up to 4 years after FDA action. Second, 1 stimulant was introduced only after FDA enforcement action. Future studies will be necessary to determine whether the FDA's public notices may, on occasion, inadvertently lead to the introduction of prohibited stimulants in supplements. Our study has several limitations. It was small; we analyzed 12 brands of supplements at 2 time points during a 3-year period. Larger studies will be necessary to confirm our findings. Furthermore, we analyzed only 1 sample of each supplement, and stimulants might vary from batch to batch.
Despite these limitations, our study provides further evidence that a regulatory system that relies on postmarket enforcement activities is insufficient to ensure the safety of dietary supplements. Practitioners should advise patients that dietary supplements may contain prohibited stimulants. 
